Potential for UGN 101 to be First Non-Surgical Therapy for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC) NEW YORK –(BUSINESS WIRE)–Dec. 19, 2019– UroGen Pharma Ltd. (Nasdaq: URGN) today announced the U.S. Food and Drug Administration ( FDA ) accepted for filing and granted
Ashish M. Kamat, MD, MBBS, provides expert insights into the current state of bladder cancer care, emphasizing the critical role of patient-centric approaches and exploring…
Ashish M. Kamat: Could MRI-first staging streamline MIBC treatment? / Ashish M. Kamat, Bladder Path, cancer, fight against cancer, Global awareness, Global
Rachel Danchek, 31, tried to manage her symptoms for years—without realizing it was a sign of ovarian cancer.
Ashish M. Kamat, MD, MBBS, provides expert insights into the current state of bladder cancer care, emphasizing the critical role of patient-centric approaches and exploring…
The guessing game is over regarding where Michelin’s stars will fall: the French tire…
Life Science Network – A web platform dedicated to life sciences.
Life Science Network – A web platform dedicated to life sciences.
Anti-tumor activity was observed across all patients with FGFR3-altered metastatic urothelial carcinoma who were treated at the dose levels of 90 mg and higher.
Anti-tumor activity was observed across all patients with FGFR3-altered metastatic urothelial carcinoma who were treated at the dose levels of 90 mg and higher.
Quick Take Video Summary from The New England Journal of Medicine — Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer
